Tech Stock News
Thursday, March 23, 2023
Orphazyme A S ADR (NASDAQ: ORPH) announced 24-month temporary consequences of an open-label extension (OLE) pilot, providing effectiveness and security statistics for its new treatment arimoclomol in Niemann-Pick disease type C (NPC) for up to 36 months. Data was presented at Parseghian Scientific Conference for NPC Research The statistics are […]
Orphazyme A S ADR (NASDAQ: ORPH) cut its financial forecasts on Friday after the U.S. wellbeing regulator abandoned its essential drug applicant, sending shares in Denmark’s first so-called meme stock plummeting 75% in early trade. The company shares, which are yet to have a medicine accepted or make cash, have […]